“Growing Preference for Targeted Biologic Therapies”
- A significant and accelerating trend in the global ustekinumab market is the increasing adoption of targeted biologic therapies that provide long-term control over chronic autoimmune and inflammatory diseases such as Crohn’s disease, ulcerative colitis, and plaque psoriasis. Ustekinumab, a human monoclonal antibody targeting interleukin-12 and interleukin-23, has become a preferred treatment due to its durable efficacy, favorable safety profile, and less frequent dosing regimen
- For instance, Ustekinumab is the only biologic currently approved for both Crohn’s disease and ulcerative colitis that targets the IL-12/23 pathway, providing consistent therapeutic benefits across multiple inflammatory conditions. Its dual cytokine inhibition has proven effective in patients who have failed other lines of therapy, making it an essential option in treatment-resistant cases
- The increasing use of real-world evidence and long-term extension studies is reinforcing physician confidence in Ustekinumab, especially for maintaining remission and improving patient quality of life. Clinical programs continue to highlight its benefits in reducing steroid dependency, preventing disease progression, and supporting mucosal healing in gastrointestinal conditions
- Healthcare systems globally are beginning to incorporate biologic optimization strategies, wherein patient biomarkers and disease activity levels guide the initiation and continuation of Ustekinumab therapy. This personalized treatment approach is helping providers improve therapeutic outcomes while minimizing unnecessary drug exposure
- The integration of Ustekinumab into updated clinical treatment guidelines by leading associations such as the American Gastroenterological Association (AGA), European Crohn’s and Colitis Organisation (ECCO), and National Psoriasis Foundation (NPF) underscores its importance in standard of care. Its role is also expanding in pediatric populations and off-label use, supported by emerging clinical data
- The demand for advanced biologics such as Ustekinumab is expected to continue rising, particularly across emerging markets, as biosimilar competition remains limited and patient access improves through expanded insurance coverage and government reimbursement programs
